On the 2nd of January 2015, the Azienda Ospedaliera di Padova (AOSP) has enrolled its first patient in the DEEP-2 study (multicentre, randomized, open label, controlled trial aimed at comparing the efficacy of deferiprone and deferasirox in paediatric patients). Other two paediatric patients have been included in the following days.
This represents an important achievement since it highlights that almost all centres, the majority of Italian ones, Atene, Cairo and Tirana, are now ready to enroll patients.
In our estimation, within April 2015 all the centres involved in the DEEP-2 clinical trial will have started the enrollment phase.
